TITLE

Nilotinib showed continued efficacy in patients with CML

PUB. DATE
December 2010
SOURCE
Hem/Onc Today;12/25/2010, Vol. 11 Issue 24, p18
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article reports on a study which revealed the continued efficacy of nilotinib in patients with chronic myelogenous leukemia (CML).
ACCESSION #
56533933

 

Related Articles

  • Ponatinib: Another new treatment for CML. Lohr, Lisa K. // Hem/Onc Today;6/10/2013, Vol. 14 Issue 11, p41 

    The article reports that three agents including bosutinib and omacetaxine was approved by the U.S. Food and Drug Administration (FDA) for use in patients with chronic myeloid leukemia.

  • Price of cancer drugs unsustainable.  // PharmacoEconomics & Outcomes News;05/11/2013, Issue 678, p1 

    The article focuses on the consensus among Chronic Myeloid Leukemia (CML) experts that the price of drugs used to treat the disease in 2013 are too high, unsustainable and are harmful to the sustainability of the U.S. national healthcare systems.

  • FDA approves nilotinib for newly diagnosed chronic phase Ph+CML.  // Hem/Onc Today;7/10/2010, Vol. 10 Issue 13, p1 

    The article reports on the approval of a new indication for the BCR-ABL inhibitor nilotinib by the U.S. Food and Drug Administration (FDA) for treatment of Philadelphia chromosome positive chronic myeloid leukemia.

  • Nilotinib rapidly produced a high response rate for Philadelphia chromosome-positive CML.  // Hem/Onc Today;12/10/2009, Vol. 10 Issue 23, p54 

    The article discusses research on the positive cytogenetic response rate and major molecular response rate in patients with Philadelphia chromosome-positive chronic myeloid leukemia treated with nilotinib for a year, conducted by G. Rosti et al, published in a a 2009 issue of the journal "Blood."

  • Nilotinib linked to fewer BCR-ABL mutations in chronic phase CML. Adams, Stacey L.; Leiser, Mark; Shafer, Emily; Taliercio, Adam; Volansky, Rob // Hem/Onc Today;4/25/2013, Vol. 14 Issue 8, p44 

    The article discusses the results of a study which showed a link between nilotinib and fewer treatment-emergent breakpoint cluster region-abelson (BCR-ABL) mutations than imatinib in chronic myeloid leukemia treatment and reduced rates of progression to accelerated phase.

  • Imatinib.  // Reactions Weekly;Nov2015, Vol. 1578 Issue 1, p164 

    The article presents case studies of two children with chronic phase chronic myeloid leukaemia who developed various toxicities during treatment with imatinib.

  • DASISION: Dasatinib superior to imatinib in newly diagnosed CML. Harris, Jason; Lawrence, Leah; Southall, Jennifer // Hem/Onc Today;6/25/2010, Vol. 11 Issue 12, p35 

    The article discusses research study on the response of patients with newly diagnosed chronic myeloid leukemia to dasatinib treatment, published in "The New England Journal of Medicine."

  • A proteomic investigation into adriamycin chemo-resistance of human leukemia K562 cells. Xingchen Peng; Fengming Gong; Gang Xie; Yuwei Zhao; Minghai Tang; Luoting Yu; Aiping Tong // Molecular & Cellular Biochemistry;May2011, Vol. 351 Issue 1/2, p233 

    This study aimed to explore the mechanism of adriamycin resistance in human chronic myelogenous leukemia cells. Proteomic approach was utilized to compare and identify differentially expressed proteins between human chronic myelogenous leukemia K562 cells and their adriamycin-resistant...

  • Ponatinib.  // Reactions Weekly;Mar2015, Vol. 1541 Issue 1, p214 

    An abstract of the article "Ponatinib-induced neutrophilic panniculitis," by M. Zhang and colleagues is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics